We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
AI summary Read the abstract
This report from the 10th CVOT Summit covers cardiovascular and kidney outcome trial results for multiple drugs, and includes discussion of environmental plastic pollution as an emerging cardiovascular risk factor. The summit highlighted growing evidence linking microplastic and chemical exposure to cardiovascular disease risk alongside sessions on diabetes, obesity, and precision medicine.
The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5-6, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recent findings from studies involving empagliflozin (EMPACT-MI), semaglutide (STEP-HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT), and finerenone (FINEARTS-HF). These studies represent significant advances in reducing the risk of major adverse cardiovascular events (MACE) and improving metabolic outcomes in heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The congress also comprised sessions on novel and established therapies for managing HFpEF, CKD, and obesity; guidelines for managing CKD and metabolic dysfunction-associated steatotic liver disease (MASLD); organ crosstalk and the development of cardio-kidney-metabolic (CKM) syndrome; precision medicine and person-centered management of diabetes, obesity, cardiovascular disease (CVD) and CKD; early detection of type 1 diabetes (T1D) and strategies to delay its onset; continuous glucose monitoring (CGM) and automated insulin delivery (AID); cardiovascular autonomic neuropathy (CAN) and the diabetic heart; and the role of primary care in the early detection, prevention and management of CKM diseases. The contribution of environmental plastic pollution to CVD risk, the increasing understanding of the efficacy and safety of incretin therapies in the treatment of CKM diseases, and the latest updates on nutrition strategies for CKM management under incretin-based therapies were also topics of interest for a vast audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians, who actively engaged in online discussions. The 11th CVOT Summit will be held virtually on November 20-21, 2025 ( http://www.cvot.org ).
More Papers Like This
new cardiovascular, kidney, and metabolic outcomes
AI summary Read the abstract
A cardiovascular outcomes summit reviewed recent clinical trials on therapies for heart failure, chronic kidney disease, and metabolic disorders, highlighting progress with semaglutide, tirzepatide, and finerenone. The meeting also addressed environmental plastic pollution as an emerging contributor to cardiovascular disease risk.
The threat of microplastics to human kidney health: Mechanisms of nephrotoxicity and future research directions
AI summary Read the abstract
This review examines the growing evidence that microplastics can reach and damage human kidneys, where they were first detected in 2023. Short-term exposure triggers oxidative stress and inflammation, while long-term exposure may lead to kidney scarring through a process called ferroptosis, a type of cell death linked to iron buildup. The authors propose that microplastics may also activate the immune system in kidneys through a gut-kidney connection, highlighting that kidney health is an important but overlooked concern in microplastic research.
From exposure to injury: signaling mechanisms of microplastic-induced renal toxicity: an extensive review
AI summary Read the abstract
Researchers reviewed experimental and mechanistic evidence on how micro- and nanoplastics damage kidneys, synthesizing a framework in which oxidative stress, inflammasome activation, mitochondrial dysfunction, and profibrotic remodeling collectively drive nephron injury — while noting that standardized biomonitoring protocols and nanoscale detection methods remain critical unresolved challenges.
Risk Factors for Cardiovascular and Metabolic Disease: Integrating Traditional and Novel Paradigms
AI summary Read the abstract
This review integrates traditional cardiovascular risk factors with emerging environmental risk factors including microplastics, air pollution, and endocrine disruptors, arguing that a significant proportion of cardiovascular events occur in individuals considered low-risk by conventional models alone.
Effects of microplastics and nanoplastics on the kidney and cardiovascular system
AI summary Read the abstract
This review summarizes evidence that microplastics and nanoplastics found in human hearts, kidneys, blood, and urine can cause oxidative stress, inflammation, cell death, and metabolic disruption. Kidney dialysis patients may face especially high exposure, and clinical evidence suggests particulate plastic exposure is a risk factor for cardiovascular disease.
Research digests by email
When a large batch of papers lands in the Atlas, we read through it and send a short write-up of what stood out.